Disease · MONDO_0004565

intestinal obstruction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. intestinal obstruction. Diseases, record MONDO_0004565. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004565

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: intestinal obstruction; Open Targets
Open Targets ID: MONDO_0004565; Open Targets
Other names: bowel obstruction; Open Targets
Disease Ontology: DOID:8437; Disease Ontology
MeSH: D007415; MeSH
NCI Thesaurus: C9175; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RISANKIZUMAB	CHEMBL3990029	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DIATRIZOATE MEGLUMINE	CHEMBL1200839	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
DIATRIZOATE SODIUM	CHEMBL1200581	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METOCLOPRAMIDE	CHEMBL86	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SPESOLIMAB	CHEMBL4297911	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IL12B	Interleukin-12	2	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 3	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	2	Interleukin-23 inhibitor	Phase 3	https://conductscience.org/library/genes/51561	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
HTR3A	5-hydroxytryptamine receptor 3A	1	Serotonin 3a (5-HT3a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3359	Drugs and targets
HTR4	5-hydroxytryptamine receptor 4	1	Serotonin 4 (5-HT4) receptor agonist	Phase 2	https://conductscience.org/library/genes/3360	Drugs and targets
IL12A	Interleukin-12	1	Interleukin-12 inhibitor	Phase 3	https://conductscience.org/library/genes/3592	Drugs and targets
IL1RAP	IL36 receptor	1	IL36 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3556	Drugs and targets
IL36R	IL36 receptor	1	IL36 receptor antagonist	Phase 2	https://conductscience.org/library/genes/8808	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
SSTR1	Somatostatin receptor	1	Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6751	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00332696	Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis	Phase 2	64	2011-06-15	Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis	OCTREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT04027348	Palliative Management of Inoperable Malignant Bowel Obstruction	Phase 2	15	2022-11-29	Malignant Bowel Obstruction	DEXAMETHASONE, METOCLOPRAMIDE, OCTREOTIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05013385	A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction	Phase 2	5	2023-06-26	Fibrostenotic Crohn´s Disease	SPESOLIMAB	Its record names the disease	ClinicalTrials.gov
NCT07177118	Risankizumab for Fibrostenotic Crohn's Disease Treatment	Phase 3	260		Crohn Disease, Crohn Disease and Ulcerative Colitis	RISANKIZUMAB, USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03741257	Comparison Between Two Concentration of Hypertonic Saline in Intestinal Obstruction Surgery	Not applicable	50		Intestinal Obstruction Fluid Management With Hypertonic Saline	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Octreotide vs Placebo: serious adverse events	6 of 32	6 of 32	64	NCT00332696

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004565

GET https://conductscience.org/api/diseases/v1/MONDO_0004565/drugs

API reference For AI assistants